Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 19/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 19/20 | 1.00 |
| ▸ | CDK5R1 | Q15078 | 19/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 17/20 | 1.00 |
| ▸ | CDK1 | P06493 | 17/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 17/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 17/20 | 1.00 |
| ▸ | GSK3A | P49840 | 3/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30319801 | 1.00 | GSK3B (1.00) | GSK3BCDK5CDK5R1CCNB2CDK1 | |
| SCHEMBL16085082 | 0.92 | GSK3B (0.85) | GSK3BCDK5CDK5R1CCNB2CDK1 | |
| SCHEMBL4177498 | 0.89 | GSK3B (0.80) | GSK3BCDK5CDK5R1CCNB2CDK1 | |
| SCHEMBL16085077 | 0.88 | GSK3B (0.78) | GSK3BCDK5CDK5R1CCNB2CDK1 | |
| SCHEMBL30319778 | 0.87 | GSK3B (1.00) | GSK3BCDK5CDK5R1CCNB2CDK1 | |
| SCHEMBL5688110 | 0.87 | GSK3B (1.00) | GSK3BCDK5CDK5R1CCNB2CDK1 | |
| SCHEMBL5688281 | 0.85 | GSK3B (1.00) | GSK3BCDK5CDK5R1CCNB2CDK1 | |
| SCHEMBL16085080 | 0.85 | GSK3B (0.74) | GSK3BCDK5CDK5R1CCNB2CDK1 | |
| SCHEMBL16085033 | 0.84 | GSK3B (0.72) | GSK3BCDK5CDK5R1CCNB2CDK1 | |
| SCHEMBL16085078 | 0.84 | GSK3B (0.85) | GSK3BCDK5CDK5R1CCNB2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2020-07-02 | — | — | US | claimed |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2016-08-25 | — | — | US | claimed |
| US-20150087687-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS (US) | 2015-03-26 | — | — | US | claimed |
| US-20060217368-A1 | Drug for nerve regeneration | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-28 | — | — | US | claimed |
| EP-1645286-A1 | DRUG FOR NERVE REGENERATION | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-04-12 | — | — | EP | claimed |
| EP-1086105-B1 | FUSED AZEPINONE CYCLIN DEPENDENT KINASE INHIBITORS | US GOV HEALTH & HUMAN SERV (US) | 2006-03-01 | — | — | EP | claimed |
| US-6610684-B2 | Antiproliferative agents | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2003-08-26 | — | — | US | claimed |
| US-20020042412-A1 | Fused azepinone cyclin dependent kinase inhibitors | HEALTH AND HUMAN SERVICES, DEPARTMENT OF, GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE, THE | 2002-04-11 | — | — | US | claimed |
| US-20230100193-A1 | NOVEL PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBIN AND DERIVATIVES THEREOF AND METHODS OF MAKING AND USING THE SAME | CYTODIGM, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20200383931-A1 | NOVEL PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBIN AND DERIVATIVES THEREOF AND METHODS OF MAKING AND USING THE SAME | CYTODIGM, INC. | 2020-12-10 | — | — | US | disclosed |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2020-07-02 | — | — | US | disclosed |
| EP-3600259-A1 | NOVEL PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBIN AND DERIVATIVES THEREOF AND METHODS OF MAKING AND USING THE SAME | Phosphorex, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | BROWN DENNIS M (US) | 2019-08-20 | — | — | US | disclosed |
| WO-2018183631-A1 | NOVEL PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBIN AND DERIVATIVES THEREOF AND METHODS OF MAKING AND USING THE SAME | PHOSPHOREX, INC. (US) | 2018-10-04 | — | — | WO | disclosed |
| US-20060217368-A1 | Drug for nerve regeneration | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-28 | — | — | US | disclosed |
| EP-1645286-A1 | DRUG FOR NERVE REGENERATION | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-04-12 | — | — | EP | disclosed |
| EP-1086105-B1 | FUSED AZEPINONE CYCLIN DEPENDENT KINASE INHIBITORS | US GOV HEALTH & HUMAN SERV (US) | 2006-03-01 | — | — | EP | disclosed |
| US-6610684-B2 | Antiproliferative agents | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2003-08-26 | — | — | US | disclosed |
| US-20020042412-A1 | Fused azepinone cyclin dependent kinase inhibitors | HEALTH AND HUMAN SERVICES, DEPARTMENT OF, GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE, THE | 2002-04-11 | — | — | US | disclosed |
| WO-1999065910-A9 | FUSED AZEPINONE CYCLIN DEPENDENT KINASE INHIBITORS | US HEALTH (US) | 2000-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230100193-A1 | NOVEL PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBIN AND DERIVATIVES THEREOF AND METHODS OF MAKING AND USING THE SAME | UGT2B7, UGT1A7, CYP3A7 | GSK3B 387/4885CDK5 785/4885CDK5R1 1060/4885 |
| US-20060217368-A1 | Drug for nerve regeneration | GSK3A, BDNF, GSK3B | GSK3B 3/4885CDK5 112/4885CDK5R1 211/4885 |
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | NEK9, NEK7, NEK3 | GSK3B 37/4885CDK5 1516/4885CDK5R1 1227/4885 |
| US-20200383931-A1 | NOVEL PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBIN AND DERIVATIVES THEREOF AND METHODS OF MAKING AND USING THE SAME | UGT2B7, UGT1A7, CYP3A7 | GSK3B 387/4885CDK5 785/4885CDK5R1 1060/4885 |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | GSK3B 37/4885CDK5 1516/4885CDK5R1 1227/4885 |
| US-20150087687-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | CYP7A1, CYP3A7, UGT2B7 | GSK3B 222/4885CDK5 3869/4885CDK5R1 4028/4885 |
| US-20020042412-A1 | Fused azepinone cyclin dependent kinase inhibitors | CCNI, CCNK, CDKN1A | GSK3B 4154/4885CDK5 42/4885CDK5R1 66/4885 |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | GSK3B 37/4885CDK5 1516/4885CDK5R1 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.